A Lloyd's Emerging Risk Report
- Posted on 26 July, 2018
A new lease of life
Synthetic biology, the application of engineering principles to genetic modification is a market forecast to grow to $39bn by 2020. In recent years scientists have been applying engineering principles to biology, creating functions that do not exist in nature to prevent and treat disease, create materials and energy sources, make crops more resistant and even support space exploration.
As this market develops the risk profile is changing. Commercialisation and digitalisation of research are enabling faster adoption and with further developments on the horizon, it is critical for insurers to consider the associated risks and opportunities.
To help the Lloyd’s market understand this rapidly evolving technology, Lloyd’s has worked with Drs John Heap and Karen Polizzi of Imperial College London, who provided their independent opinion, to produce ‘A new lease of life’. The report also covers recent developments since the Lloyd’s 2009 report and commercial applications, including an overview of the associated risks.
The report is aimed at underwriters, brokers and exposure managers who are or will be exposed to synthetic biology, to encourage them to work with manufactures to support the responsible development of new technologies and solutions.
Download the report here
Share this article:
People also read
Evonetix establishes scientific advisory board
CAMBRIDGE, UK, 20 December 2018 – EVONETIX LTD (‘Evonetix’), the Cambridge-based company pioneering an innovative approach to scalable and high-fideli...
Synthetic biology start-up Colorifix raises $3m Series A round to scale its revolutionary textile dyeing solution
Colorifix, a company that has developed the first commercial biological dyeing process, has raised a Series A round of $3 million from impact and stra...
Evonetix wins Best Emerging Synthetic Biology Company at the OBN Awards
London, UK, 12th October 2018 / Sciad Newswire / SynbiCITE would like to congratulate Evonetix on winning ‘Best Emerging Synthetic Biology Company’ at...